Cancer Therapeutics

癌症治疗项目的三个目标是：1)加强和促进基础科学家和临床研究人员在癌症治疗方面的项目间和项目间的互动与合作；2)促进新治疗方法的发现、发展和应用；3)开展新的治疗药物和新的治疗方法的转化和实验室临床研究。这些目标是通过三个研究主题实现的。主题1侧重于目标识别和药物发现的技术发展，目标是将这些新技术（如组合化学，药物化学，计算生物学，结构生物学，纳米技术和高通量测定）应用于主题2中的特定药物开发项目。例如，在主题2中，我们正在开发：癌细胞表面靶向配体，用于癌症药物递送和成像的新型靶向纳米载体，酪氨酸激酶抑制剂，以及用于癌症疫苗和免疫治疗的纳米颗粒。在主题3中，我们使用一个由分子生物学家、转化科学家、药理学家和临床研究人员组成的合作小组来促进实验室驱动的临床研究的设计和实施。鉴于该项目在药物发现和药物开发方面的临床前专业知识，将有希望的新治疗方法转化为临床试验和相关的实验室相关研究的潜力很大。这种转化的一个例子是开发新的纳米紫杉醇配方，很快将在人体中进行测试。此外，这组研究人员所代表的专业知识为从NCI或行业获得新的治疗药物提供了一个渠道。为临床研究和转化研究的特定项目领域提供临床试验平台，包括药物开发奖励（N01, U01, U10）和研究者发起的试验。该项目有46名成员，分别来自加州大学戴维斯分校的13个不同部门和LLNL的1个部门。它有25个国家语言委员会资助的项目，资助金额为390万美元（同行评审资助总额为880万美元）。在上一个筹资期间的728份出版物中，44%是方案间出版物，29%是方案内出版物。

The three goals of the Cancer Therapeutic Program are: 1) to enhance and facilitate programmatic and interprogrammatic interaction and collaboration between basic scientists and clinical investigators in cancer therapeutics; 2) to promote the discovery, development, and application of novel therapeutic approaches; and 3) to develop translational and laboratory-based clinical investigations of new therapeutic agents and new therapeutic approaches. These goals are achieved through three Research Themes. Theme 1 is focused on technology development for target identification and drug discovery, with the goal of applying these new technologies (such as combinatorial chemistry, medicinal chemistry, computational biology, structural biology, nanotechnology, and high-throughput assays) to specific drug development projects in theme 2. For example, in theme 2, we are developing: cancer cell surface targeting ligands, novel targeting nanocarriers for cancer drug delivery and imaging, tyrosine kinase inhibitors, and nanoparticles for cancer vaccine and immunotherapy. In Theme 3, we use a collaborative group of molecular biologists, translational scientists, pharmacologists, and clinical investigators to facilitate the design and conduct of laboratory-driven clinical investigations. In view of the preclinical expertise in drug discovery and drug development available within the Program, there is great potential to translate promising new therapeutic leads into clinical trials and associated laboratory correlative studies. One example of such translation is the development of novel nanoformulations of paclitaxel soon to be tested in human. Furthermore, the expertise represented within this group of investigators provides a conduit for acquisition of new therapeutic agents from the NCI or industry. Providing a platform for clinical trials are specific project areas in clinical investigation and translational studies, including drug development awards (N01, U01, U10) and investigator-initiated trials. The program has 46 members from 13 different departments at UC Davis and 1 department at LLNL. It has 25 NCl-funded projects for $3.9 million ADC (total peer-reviewed funding, $8.8 million ADC). Of the 728 publications for the last funding period, 44% are inter-programmatic and 29% are intra-programmatic.